Ginkgo Tree Pharmaceutical

Ginkgo Tree Pharmaceutical (Suzhou) Co., Ltd. is a Chinese biotechnology company founded in 2009 and headquartered in the Suzhou Industrial Park. The company specializes in the discovery and development of innovative small molecule drugs for the treatment of viral infections, including Hepatitis B (HBV), Hepatitis C (HCV), and influenza. Its lead products include Coblopasvir, an HCV NS5A inhibitor approved in China, and Suraxavir Marboxil, an influenza endonuclease inhibitor developed in partnership with Jiangxi Qingfeng Pharmaceutical. Ginkgo Tree is supported by prominent venture capital firms such as Lilly Asia Ventures and Pick-up Capital.